Insider Selling: Cencora, Inc. (NYSE:COR) EVP Sells 5,000 Shares of Stock

Cencora, Inc. (NYSE:COR) EVP Silvana Battaglia sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the transaction, the executive vice president now directly owns 15,374 shares in the company, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Silvana Battaglia also recently made the following trade(s):

• On Friday, December 20th, Silvana Battaglia sold 1,678 shares of Cencora stock. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16.

Cencora Stock Performance

NYSE COR traded up $2.91 during trading on Monday, reaching $244.34. The company’s stock had a trading volume of 1,068,423 shares, compared to its average volume of 1,476,492. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $262.26. The firm has a 50 day moving average price of $239.81 and a 200 day moving average price of $237.47. The firm has a market capitalization of $47.38 billion, a price-to-earnings ratio of 34.76, a price-to-earnings-growth ratio of 1.31 and a beta of 0.49. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date is Friday, February 14th. Cencora’s payout ratio is currently 31.29%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Swedbank AB raised its position in shares of Cencora by 2.3% in the 3rd quarter. Swedbank AB now owns 1,394,449 shares of the company’s stock valued at $313,863,000 after buying an additional 31,104 shares in the last quarter. Allworth Financial LP raised its position in Cencora by 22.8% during the third quarter. Allworth Financial LP now owns 1,672 shares of the company’s stock valued at $376,000 after purchasing an additional 310 shares in the last quarter. Louisiana State Employees Retirement System raised its position in Cencora by 4.3% during the third quarter. Louisiana State Employees Retirement System now owns 9,800 shares of the company’s stock valued at $2,206,000 after purchasing an additional 400 shares in the last quarter. Parcion Private Wealth LLC lifted its stake in Cencora by 90.9% during the third quarter. Parcion Private Wealth LLC now owns 1,791 shares of the company’s stock worth $403,000 after purchasing an additional 853 shares during the last quarter. Finally, Forsta AP Fonden boosted its holdings in shares of Cencora by 9.0% in the 3rd quarter. Forsta AP Fonden now owns 69,270 shares of the company’s stock valued at $15,591,000 after purchasing an additional 5,700 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the stock. Robert W. Baird increased their price target on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Evercore ISI upped their target price on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. JPMorgan Chase & Co. lifted their price target on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. UBS Group boosted their target price on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, Wells Fargo & Company upped their price objective on shares of Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a report on Wednesday, January 29th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $277.90.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.